---
title: 'Report: supervised classification of cancer data'
author: "Ana√Øs REY"
date: "`r Sys.Date()`"
output:
  html_document:
    code_folding: hide
    fig_caption: yes
    highlight: zenburn
    number_sections: no
    self_contained: no
    theme: cerulean
    toc: yes
    toc_depth: 3
    toc_float: yes
  pdf_document:
    fig_caption: yes
    highlight: zenburn
    toc: yes
    toc_depth: 3
font-import: http://fonts.googleapis.com/css?family=Risque
font-family: Garamond
subtitle: DUBii 2020 - Module 3 - Analyse statistique avec R - Evaluation
editor_options:
  chunk_output_type: console
transition: linear
---

```{r settings, include=FALSE, echo=FALSE, eval=TRUE}
message("Loading required libraries")

requiredLib <- c(
  "knitr",
  "rpart",
  "e1071",
  "rpart.plot",
  "randomForest", 
  "grDevices", 
  "FactoMineR",
  "factoextra",
  "e1071",
  "caret",
  "RColorBrewer")

for (lib in requiredLib) {
  if (!require(lib, character.only = TRUE)) {
    install.packages(lib, )
  }
  require(lib, character.only = TRUE)
}

options(width = 300)
# options(encoding = 'UTF-8')
knitr::opts_chunk$set(
  fig.width = 7, fig.height = 5, 
  fig.path = 'figures/learning_',
  fig.align = "center", 
  size = "tiny", 
  echo = TRUE, 
  eval = TRUE, 
  warning = FALSE, 
  message = FALSE, 
  results = TRUE, 
  comment = "")

options(scipen = 12) ## Max number of digits for non-scientific notation
# knitr::asis_output("\\footnotesize")

```

```{r load_solutions}
#### Just for the trainer: if the solution file exists, load it ####
solutionFile <- "van-Helden-Jacques_evlaluation-m3_solutions.R"
if (file.exists(solutionFile)) {
  # read_chunk(solutionFile)
}

```


## Principle of the evaluation

We propose here a structure of scientific report for the final evaluation of the third module "Analyse statistique with R". 

The report is conceived in order to be compiled as is. 

To ease your task and ensure everyone starts on the same basis,the notebook already inculdes the following basic tasks: 

- data loading
- pre-processing: normalisation, dimension reduction

We ask everyone to fill in the missing parts with personnaly written code.

Each trainee will choose a given machine learning method (SVM, KNN, Random Forest, or any other one of your choice), tune its parameters and evaluate its performances. The results will be collected in a comparative table in order to gain a general insight on the respective merits of the methods, based on the individual results. 

You will then use your model to assign each sample to one of the 4 cancer types:  Basal.like, HER2pos, Luminal.A ou Luminal.B.


### Evaluation criteria

- **Reusability of the code**: the trainers should be able to run your R markdown on their instance of RStudio

- **Clarity of the code**: the code should be understandable for someone familiar with R programming. Variable names should indicate their content. 

- **Code structuration**: the code should be well structured. For example, if a given piece of code has to run at several places in your script, try to encapsulate it in a function rather than duplicating the code. 

- **Code documentation**: the code should be documented by explaining what each piece of code aims at. The implementation choices should be documented. 

- **Relevance of the statistical approaches**: the markdown should explain why a given statistical method is appropriate to the addressed biological question. Don't hesitate to comment the basic assumptions underlying the different methods, and the adequacy of your data to these assumption. 

- **Interpretation of the results**: for each task, we will ask you to interpret the results and to highlight their biological relevance. 


## Goals of the analysis

Your work will include the following tasks. 

1. **Data exploration**: compute descriptive statistics and use different graphical representations to grab general properties of the data distribution. 


    - histogram of the data
    - dot plot of the gene-wise variance versus mean
    - PC plots


2. **Gene clustering**: 

    - run some clustering algorithm in order to identify groups of genes having similar expression profiles across the samples
    - cluster the samples in order to see if a non-supervised approach reveals subsets of cancer types, and compare the clusters with the annotated cancer types. 


3. **Supervised classification**

    - choose a supervised classification method among KNN, SVM, Random Forest, or any other method if you feel adventurous.


## Specification of the working directories

We propose hereafter a piece of code to instantiate the working directories for this analysis in your account. In principle this code should work on any Unix-like operating system (Linux, Mac OX X), it might require some slight adaptation for Windows operating systems. 

```{r directories}
## Create a vector with all the user-specific directories, which can be exported in the report afterwards
dir <- vector()

## Specify your home directory
dir["home"] <- "~" # This should probably be modified for Windows OS. 

## Specify the local directory for the personal work
## Don't hesitate to modify this according to your own file organisation
dir["base"] <- file.path(dir["home"], "DUBii", "m3-stat-R", "personal-work")  

## Directory with the results of all analyses
dir["results"] <- file.path(dir["base"], "results")
dir.create(dir["results"], showWarnings = FALSE, recursive = TRUE)

## Specify a local directory to download the data
dir["BICdata"] <- file.path(dir["base"], "data", "BIC")
message("Local data directory for BIC data\t", dir["BICdata"])
dir.create(dir["BICdata"], showWarnings = FALSE, recursive = TRUE)

## Print out a table with the working directories
kable(data.frame(dir), col.names = "Directory", caption = "Directories")

```



## Data set

In this work we will develop statistical models to predict cancer types using data from the TCGA study (*The Cancer Genome Atlas*; https://cancergenome.nih.gov/) which includes RNA-seq data from breast cancer patients (**Breast Invasice Cancer** or **BIC**). There are two invasive cancer types involved: ductal and lobular carcinomas. 

Original papers for these studies are here: 

- <https://www.nature.com/articles/nature11412>
- <https://www.cell.com/cell/fulltext/S0092-8674(15)01195-2>

We prepared the files containing the BIC transcriptome profiles, and selected a subset of 1000 genes to reduce the size of the data files.  

* file `BIC_log2-norm-counts_edgeR_DEG_top_1000.tsv.gz` corresponds to the RNA quantification  in 819 samples (columns), for the 1000 most significant genes (lines) returned by differential analysis.
* file `BIC_sample-classes.tsv.gz` contains the tags of the 819 samples.
* file `BIC_edgeR_DEG_table.tsv.gz`  contains the edgeR results of differential expression analysis.


The code below enables you to download the data and install it on your own computer. Note tht th data will be downloaded only once. 


```{r download_data}
## Files required for the analyses
message("Downloading BIC data")

dataFiles <- c(
  "expression" = "BIC_log2-norm-counts_edgeR_DEG_top_1000.tsv.gz", ## Expression values
  "sample classes" = "BIC_sample-classes.tsv.gz", ## Sample descriptions
  "DEG table"  = "BIC_edgeR_DEG_table.tsv.gz"  ## edgeR results of differential expression analysis
)


for (dataFile in dataFiles) {
  localFile <- file.path(dir["BICdata"], dataFile)
  if (file.exists(localFile)) {
    message("File already here, not downloading\n\t", localFile, "\n")
  } else {
    githubURL <- file.path("https://github.com/DU-Bii/module-3-Stat-R/raw/master/stat-R_2020/data/TCGA_BIC_subset/", dataFile)
    message("Downloading data file from github:\n\t", githubURL)
    download.file(url = githubURL, destfile = localFile)
  }
}
```





## Data preprocessing

The data was pre-processed in order to provide you with a dataset ready-to-use for the multivariate analysis tasks. 

In short, the pre-processing included the following steps. 

1. Download of the raw counts per gene from the ReCount database

2. Selection of the subset of samples belonging to the **Breast Invasive Cancer** (**BIC**) study. 

3. Assignment of a cancer type, based on three immuno markers (documented in the sample description table).

4. Filtering out of the "undetected" genes, i.e. genes having either zero counts in more than 95% of the samples, or a mean count $\se 10$ across all the BIC samples. 

5. Count standardisation. To compensate for difference in sequencing depth, we applied a sample-wise standardisation with `DESeq2::estimateSizeFactors()`. 

6. Log2 transformation. Standardised counts were log2-transformed in order to normalise the values. Log2-transformed data are more appropriate for clustering and supervised classification. 

7. Feature selection. In order to select relevant subset of genes, we ran multi-group differential analysis with edgeR. Note that this analysis was led with the raw counts (edgeR and DESeq2 have their own built-in normalisation procedure, and should never be fed with normalised data). 

Additional details and the full code used for preprocessing can be found on the DUBii study case repository: <https://du-bii.github.io/study-cases/Homo_sapiens/TCGA_study-case/import_TCGA_from_Recount.html>



## Data loading

The data were loaded from the folder `r dir["BICdata"]`. 

```{r data_loading}
## Load expression data
## Note: we use the option check.name=FALSE to avoid converting 
## hyphens to dot in the sample IDs (column names)
BIC.expr <- read.table(
  file = file.path(dir["BICdata"], dataFiles["expression"]), 
  check.names = FALSE, # Added by JvH 2020-07-24
  header = TRUE)
# dim(BIC.expr)
# colnames(BIC.expr)


## Load sample description table, whichb includes cancer class + immuno markers
## Note: we set the option stringsAsFactor=FALSE to facilitate 
## subsequent use of the cancer.type column.
BIC.sample.classes <- read.table(
  file.path(dir["BICdata"], dataFiles["sample classes"]), 
  stringsAsFactors = FALSE, # Added by JvH 2020-07-24
  header = TRUE)
# dim(BIC.sample.classes)
# names(BIC.sample.classes)
# head(BIC.sample.classes)
# class(BIC.sample.classes$cancer.type)

## Define sample colors and 1-letter symbols
class.symbols <- c(
  "Basal.like" = "B",
  "HER2pos" = "H",
  "Luminal.A" = "A",
  "Luminal.B" = "B",
  "Unclassified" = "U"
)
BIC.sample.classes$symbol <- class.symbols[BIC.sample.classes$cancer.type]
table(BIC.sample.classes$symbol)

## Define a color for each cancer class and assign colors to samples accordingly.
class.colors <-  c(
  "Basal.like" = "brown",
  "HER2pos" = "darkgreen",
  "Luminal.A" = "blue",
  "Luminal.B" = "violet",
  "Unclassified" = "grey"
)
BIC.sample.classes$color <- class.colors[BIC.sample.classes$cancer.type]


## Load differential expression analysis results from DESeq2
BIC.deg <- read.table(file.path(dir["BICdata"], dataFiles["DEG table"]),
                      header = TRUE)
# head(BIC.deg)

#### Reorder samples in order to group them by class ####
sampleNamesByClass <- rownames(BIC.sample.classes)[order(BIC.sample.classes$cancer.type)]
length(sampleNamesByClass)
BIC.expr <- BIC.expr[, sampleNamesByClass]
BIC.sample.classes <- BIC.sample.classes[sampleNamesByClass, ]

kable(dataFiles, col.names = "File", caption = "Data files")

```


The expression file contains `r nrow(BIC.expr)`  rows (genes) x `r ncol(BIC.expr)`  columns (samples). 

The sample description table contains `r nrow(BIC.sample.classes)`  rows (samples) x `r ncol(BIC.sample.classes)`  columns (description fields). The first column indicates the cancer type, and the three following one indicate the values (positive/negative) for three marker genes used as diagnostic markers for the cancer type (*ER1*, *PR1* et *Her2*). 

```{r}
kable(head(BIC.sample.classes, n = 5), caption = "First rows of the sample description table. ")
```


We can count the number of samples per cancer type

```{r class_summary}
kable(sort(table(BIC.sample.classes$cancer.type), decreasing = TRUE), 
      col.names = c("Cancer type" , "Nb samples"))
```


There are `r length(unique(BIC.sample.classes$cancer.type))` cancer types, including a "Unclassified", for the samples having a combination of markers inconsistent with the defined subtypes. This might bias the result since this "class" is likely to contain a mixture of different cancer types. We will thus temporarily suppress these samples from the dataset, but we will come back to it at the end of the work, since they provide an excellent opportunity to run the classifier for predictive purpuses (assign unclassified samples to one of the training classes). 


The code below creates a data set from which the `Unclassified` samples has been suppressed. 


```{r remove_unclassified_samples}
## Generate a Boolean vector indicating which samples are unclassfied
unclassified <- BIC.sample.classes$cancer.type == "Unclassified"

## Count the number of genes having or not the unclassified label
# table(unclassified)

## Get the indices of the corresponding rowss
ind.uncl <- which(unclassified)

## Count the number of unclassified samples
# length(ind.uncl)

## Create a separate data frame 
BIC.sample.classes.filtered <- BIC.sample.classes[-ind.uncl,]
# dim(BIC.sample.classes.filtered)

BIC.expr.filtered <- BIC.expr[, -ind.uncl] 
# dim(BIC.expr.filtered)
```



## Data reduction


We propose three methods to reduce the data dimensions.

a. **Differentially Expressed Genes** (**DEG**). Selection of the most signficant genes reported by DESeq2 (multi-group differential analysis). This has already been done for you, we provide the table with the 1000 top significant genes.

b. **Variance-ordered**: genes were sorted by decreasing variance (unsupervised criterion). To avoid handling big files, we will apply a re-ordering of the 1000 top-ranking DEG genes, and see whether the genes wiht the highest variance provide good classifiers. 

c. **PCs** Principal components. We will use a restricted number of principal components and see if they capture a sufficient information to train a classifier. 

You will use these respective datasets at different stages of your report.


### DEG selection

The code below sorts the expression table by increasing values of the FDR (column `padj` of the table `BIC.deg`) found in the differential expression table (variable `BIC.deg`). 

Note that DEG table contains `r nrow(BIC.deg)` genes, whereas the expression table was restricted to `r nrow(BIC.expr.filtered)` genes. We thus used a trick to select the right genes and sort them. The result is a table with `r nrow(BIC.expr.filtered)` rows (genes) and `r ncol(BIC.expr.filtered)` columns (samples), sorted by increasing FDR (not in the table). 

```{r top_deg}
## Select in the DEG table (that contains ~20,000 genes) the subset that is found in the expression table (1000 genes)
BIC.deg.filtered <- subset(
  BIC.deg, 
  row.names(BIC.deg) %in% row.names(BIC.expr.filtered))
# dim(BIC.deg.filtered)
# View(BIC.deg.filtered)

## Sort gene names by increasing value of edgeR padj
geneOrder <- rownames(BIC.deg.filtered)[order(BIC.deg.filtered$padj, decreasing = FALSE)]
# head(geneOrder)

## Sort the expression table according to the DEG gene order
BIC.expr.DEGsorted <- BIC.expr.filtered[geneOrder, ]
# View(BIC.expr.DEGsorted)

```

### Variance-based ordering

It is now your turn to process the data. Create another table with the filtered expression table sorted by decreasing variance. 

```{r variance_ordering, eval=TRUE}
## Sort gene names by decreasing variance 
geneOrder.var <- rownames(BIC.expr.filtered)[order(apply(BIC.expr.filtered, 1, var), decreasing = TRUE)]

## Sort the expression table according to the decreasing variance gene order
BIC.expr.VARsorted <- BIC.expr.filtered[geneOrder.var, ]
```


### Principal components


Run principal component analysis on the filtered expression table and create a separate table named `BIC.expr.PCs` with the coordinates of each sample in the principal component space.

```{r pc_computation}
## The samples should come as row so we transpose the expression matrix on which we compute the components 
result.pca <- PCA(t(BIC.expr.filtered), scale.unit = FALSE, ncp = ncol(BIC.expr.filtered), graph = FALSE)

## Table with the coordinates of each sample in the PC space
BIC.expr.PCs <- result.pca$ind$coord

# We kept all dimensions in the results (whereas by defaultin the PCA() it is 5 dimensions), so we should have 712-1 dimensions, we check that by looking at the dim() of the table with the coordinates
dim(BIC.expr.PCs)

# We plot eigen values 
fviz_eig(result.pca, addlabels = TRUE)
```

We see that the two first dimensions represent around 24% of the total variance and if we take the 4 first dimensions, we increase the % of total variance to around 38%.

## PC plots

Generate PC plots with the following components. Label the samples according to their annotated class.

- PC2 vs PC1
- PC4 vs PC3
- PC6 vs PC5


```{r pc_plots}
# function used to do PC plots based on the wanted components
plot_pca <- function(x,y){
  fviz_pca_ind(result.pca, axes = c(x,y), 
             col.ind = BIC.sample.classes.filtered$cancer.type,
             label="none") # to avoid having the name of each sample which in our case make the plot impossible to read and very long 
}

plot_pca(x=1, y=2) # Plot PC2 vs PC1
plot_pca(x=3, y=4) # Plot PC4 vs PC3
plot_pca(x=5, y=6) # Plot PC6 vs PC5
```


### Your interpretation

Les 2 premi√®res composantes capturent environs 24% de la variance totale et semblent indiquer que les √©chantillons des patientes avec les cancers LuminalA et B sont plus proches entre elles que celles avec les cancers de type Basal.like. Les patientes avec le cancer HER2pos ont une position interm√©diaire entre les patientes au cancer Luminal (A et B) et type Basal.like. On voit aussi qu'il y a une variation importante des patientes au sein des cancer. Enfin, on voit que la variance est bien partag√©e entre les diff√©rentes composantes (13.8, 10.4, 8.5, 5, ... %) ce qui tend √† indiquer que m√™me si le facteur type de cancer est le plus important (car vu sur les 2 premiers axes), on voit aussi que d'autres facteurs jouent un r√¥le important dans la variance.


## Clustering


### Gene clustering

Select the 500 most significant genes based on the adjusted p-value and run hierarchical clustering using the following dissimilarity metrics

- Euclidian distance ($d_E$)
- Pearson's correlation-derived  ($d_P = 1 - c_P$) where $c_P$ is Pearson's correlation)
- Spearman's correlation-derived  ($d_S = 1 - c_S$) where $c_S$ is Spearman's correlation)

Draw the results in a heatmap, where the rows correspond to genes and colums to samples. Make sure that the heatmap reflects the gene tree, but leaves the samples in their original order (to keep together the samples of the same cancer type). 

Tips: `cor()`, `hclust()`, `heatmap()`,`heatmap.2()` or the other heatmap functions seen in the practicals. 


```{r gene_clustering}
## We select the first 500 most significant genes based on the adjusted pvalue by taking the file already sorted by decreasing pvalue and we take only the 500 first rows
BIC.expr.DEGsorted.500genes <- BIC.expr.DEGsorted[1:500,]

# We choose a new paletee of color for the heatmaps
coul <- colorRampPalette(brewer.pal(8, "RdBu"))(25)

# We run the hierarchical clustering using the 3 different dissimilarity metrics 
# (pearson, spearman and euclidean distance) and using the Ward.D2 method.
# The heatmap reflects the gene tree, but leaves the samples in their original order (to keep together the samples of the same cancer type). 

heatmap(as.matrix(BIC.expr.DEGsorted.500genes), 
        distfun = function(x) { as.dist(1 - cor(t(x), method = "pearson")) }, 
        hclustfun = function(x) hclust(x, method="ward.D2"),
        Colv=NA,
        ColSideColors=BIC.sample.classes.filtered$color,
        col=coul, 
        main="Genes clustering with Pearson Correlation")
  
heatmap(as.matrix(BIC.expr.DEGsorted.500genes), 
        distfun = function(x) { as.dist(1 - cor(t(x), method = "spearman")) }, 
        hclustfun = function(x) hclust(x, method="ward.D2"),
        Colv=NA,
        ColSideColors=BIC.sample.classes.filtered$color,
        col=coul, 
        main="Genes clustering with Spearman Correlation")
  
heatmap(as.matrix(BIC.expr.DEGsorted.500genes), 
        distfun = function(x) { dist(x, method = "euclidean") }, 
        hclustfun = function(x) hclust(x, method="ward.D2"),
        Colv=NA,
        ColSideColors=BIC.sample.classes.filtered$color,
        col=coul, 
        main="Genes clustering with Euclidean distance")

```

#### Gene clustering: your interpretation

Interpret the results (1 or 2 paragraphs): do you see a correspondence between the gene expression profiles and cancer classes? 

Premi√®rement, j'ai tendance √† observer une diff√©rence entre les 3 m√©triques de dissimilarit√© avec la distance euclidienne montrant un patron assez diff√©rent qu'avec les 2 autres m√©triques. 

Sinon, il semble que le clustering hierarchique r√©v√®le 2 groupes (les 2 premi√®res branches de l'arbre) avec un groupe de g√®nes qui semblent plus exprim√©s au sein des √©chantillons provenant des types de cancer Basal.like (brown color) and HER2pos (dark-green color) et un groupe de g√®nes plus exprim√©s au sein des √©chantillons provenant des types de cancer Luminal A et B (Violet et blue colors). 


### Sample clustering

Apply the same 3 metrics to cluster samples based on the expression levels. 

For each metrics, prune the tree to obtain 4 clusters, and compare them with the annotated cancer class (tips: `cutree()`, `table()`, `kable()`). 

```{r sample_clustering}
## We compute the euclidean distance 
BIC.dist.euclid <- dist(t(BIC.expr.DEGsorted), method="euclidean")

## We compute Spearman correlation coefficient  &
# Derive a dissimilarity value from the corrrelation
BIC.cor.spear <- cor(BIC.expr.DEGsorted, method = "spearman")
BIC.dist.spear <- as.dist(1 - BIC.cor.spear)

## We compute Pearson correlation coefficient  &
# Derive a dissimilarity value from the corrrelation
BIC.cor.pear <- cor(BIC.expr.DEGsorted, method = "pearson")
BIC.dist.pear <- as.dist(1 - BIC.cor.pear)

## We run hierarchical clustering on the expression data using ward.D2 method
BIC.eucli.hclust.wardD2 <- hclust(BIC.dist.euclid, method="ward.D2")
BIC.spear.hclust.wardD2 <- hclust(BIC.dist.spear, method="ward.D2")
BIC.pear.hclust.wardD2 <- hclust(BIC.dist.pear, method="ward.D2")

## We apply cutree at 4 levels to get 4 clusters 
BIC.eucli.cutree4 <- cutree(BIC.eucli.hclust.wardD2, k = 4)
BIC.spear.cutree4 <- cutree(BIC.spear.hclust.wardD2, k = 4)
BIC.pear.cutree4 <- cutree(BIC.pear.hclust.wardD2, k = 4)

## We look if the 4 clusters differentiate well the 4 classes of cancer and if there is differences between the 3 metrics used 
kable(table(BIC.eucli.cutree4, 
            BIC.sample.classes.filtered$cancer.type),
      caption= "Number of samples per cluster using the Euclidean distance in function of their associated type of cancer")

kable(table(BIC.spear.cutree4, BIC.sample.classes.filtered$cancer.type),
      caption= "Number of samples per cluster using the Spearman Correlation distance in function of their associated type of cancer")

kable(table(BIC.pear.cutree4, BIC.sample.classes.filtered$cancer.type),
      caption= "Number of samples per cluster using the Pearson Correlation in function of their associated type of cancer")
```

#### Sample clustering: your interpretation

Is there a good correspondence between sample clusters and  annotated cancer types? Is there a strong impact of the dissimilarity metrics? Which one performs best?

De mani√®re g√©n√©rale, il n'y a pas de tr√®s bonne correspondance entre les 4 groupements effectu√©s et les 4 types de cancer √† part pour le cancer de type Basal.like pour qui on voit que pour les 3 m√©triques utilis√©es les √©chantillons sont toujours assez bien regroup√©s dans un m√™me cluster. Il semble avoir un impact important de la m√©trique utilis√©e surtout entre les correlations (spearman et pearson) et la distance euclidienne. La derni√®re distingue beaucoup moins les types de cancer HER2pos et Luminal (A et B).
Je dirais que les m√©triques corr√©lation que ce soit celle de spearman ou pearson permettent de mieux distinguer les types de cancer en comparaison √† la distance euclidienne.


## Supervised classification

### Preparation of training and testing subsets

* The **learning set** is the set which will allow to train the models. It will be made of 2/3 of the samples randomly selected.  

* The **testing set** is the set which will allow to estimate the unbiased performances of the models. It will be made of the remaining 1/3 of the samples.  

Split the filtered data set into training (2/3) and a testing (1/3) subsets with a balanced representation of the cancer types (stratified subsampling). 

```{r train_test_sets}

# we create an empty result to stock the samples subset for the training dataset
res.training <- NULL

for (i in unique(BIC.sample.classes.filtered$cancer.type)){
  # we select only the samples belonging to one type of cancer
  df.type <- BIC.sample.classes.filtered[BIC.sample.classes.filtered$cancer.type == i,]
  # we randomly select 2/3 of the samples coming from this type of cancer
  df.sub <- sample(1:nrow(df.type), size = 2/3 * nrow(df.type))
  # we take the rowanmes of those selected samples 
  df.sub <- rownames(df.type)[df.sub]
  res.training <- c(res.training, df.sub)
}

# We subset from the expression level dataset the samples selected for the training set
BIC.expr.training <- BIC.expr.DEGsorted[,res.training]
dim(BIC.expr.training) # we check the dimensions and we should have 473 samples (as it is 2/3 of 712 samples)

BIC.samples.training <- BIC.sample.classes.filtered[rownames(BIC.sample.classes.filtered) %in% res.training,]

BIC.expr.training.2 <- data.frame(BIC.samples.training[,1], t(BIC.expr.training))
names(BIC.expr.training.2)[1] <- "cancer.type"


# We subset from the expression level dataset the samples selected for the testing set
BIC.expr.testing <- BIC.expr.DEGsorted[,!colnames(BIC.expr.DEGsorted) %in% res.training]
dim(BIC.expr.testing) # we check the dimensions and we should have 239 samples (as it is 1/3 of 712 samples)

BIC.samples.testing <- BIC.sample.classes.filtered[!rownames(BIC.sample.classes.filtered) %in% res.training,]

BIC.expr.testing.2 <- data.frame(BIC.samples.testing[,1], t(BIC.expr.testing))
names(BIC.expr.testing.2)[1] <- "cancer.type"
```

### Evaluation of the performances

In this section, we will perform here a manual evaluation of the classifier in order to make sure we master the different steps. In the next section we will use the  `tune()` utilities in order to identify the optimal parameter values. 

1. Use the training subset to train a classifier of your choice (KNN, SVM, Random Forest or an other one if you feel adventurous). 

```{r training}
# we used Random Forest as a classifier for our training dataset with keeping the default parameters for mtry and mtree 
BIC.expr.training.2$cancer.type = factor(BIC.expr.training.2$cancer.type) # randomForest expects categorical outcome variables to be factors so we convert the cancert.type column

rf.fit.train <- randomForest(cancer.type ~ ., data = BIC.expr.training.2)
rf.fit.train
```


2. Use the resulting model to predict the cancer type for the samples of the testing set. 

```{r testing}
pred.rf <- predict(rf.fit.train, newdata = BIC.expr.testing.2)
table(pred.rf)
```


3. Build a confusion matrix to compare the predicted classes and annotated classes for the testing set. 

```{r confusion_matrix}
tc.test <- table(pred.rf, BIC.expr.testing.2$cancer.type)
```


4. Compute the misclassification error rate (MER). 


```{r classifier_evaluation}
# We take the number of sample for which the model did not found the good cancer type and we divide it by the total of sample to get the rate of error

sum(pred.rf != BIC.expr.testing.2$cancer.type)/length(BIC.expr.testing.2$cancer.type)

# Other option we do 1 - rate of accuracy
1 - sum(diag(tc.test))/sum(tc.test)

```


#### Your interpretation

Interpret the results: how well does the classifier perform? Is there a bias towards some cancer types?

Avec un taux d'erreur de 25%, je dirais que le "classifier" fonctionne moyennement bien pour pr√©dire le type de cancer des √©chantillons car cela voudrait dire que pour 1 personne sur 4 on pr√©dirait un "mauvais" cancer. De plus, les cancers HER2Pos ne sont jamais bien pr√©dis. IL semble y avoir un biais vers Luminal A car un bon nombre d'√©chantillon venant d'autres cancers sont pr√©dis comme Luminal A notamment pour les cancers Luminal B (39 sur 40 √©chantillons)

### Tuning of the parameters

Test the impact of a parameter on the performances by repeating the steps above with different values of this parameter. The parameter to be tested will depend on the algorithm you chose. 

- `svm()`: test each one of the 4 supported kernels
- `knn()`: test the impact of the number of neighbors
- `randomForest()`: test the impact of the `mtry`parameter 

Tips: `tuneRF()` or `tune.randomForest()`, `tune.knn()`, `tune.svm()`

```{r classifier_tuning}

# Algorithm Tune (tuneRF)
set.seed(123) # it allow to have the same result --> defined as 
# "Set the seed of R‚Äòs random number generator, which is useful for creating simulations or random objects that can be reproduced."

bestmtry <- tuneRF(BIC.expr.training.2[,-1], BIC.expr.training.2$cancer.type)
print(bestmtry)

```


#### Your interpretation

Interpret the results: do the tested parameters affect a lot the performances (are the results robust or sensitive to the choice of the parmeter value)? Do you see a rationale for the optimal values returned by the tune functions?

Je trouve que les r√©sultats sont relativement robustes vu qu'en modifiant le param√®tre par d√©faut (sqrt(1000) = 31) et donc en testant des valeurs de mtry 2X plus grande ou 2X plus petite, le taux d'erreur reste dans le m√™me ordre de grandeur. Du coup, je resterais avec le param√®tre par d√©faut.

### Prediction

1. Train the classifier with all the samples of the filtered data set
2. Use the resulting model to predict the cancer type for the unclassified samples. 

```{r prediction}
### 1. We train the classifier with all samples 

# We add the type of sample and we transpose the BIC.exp for the model
BIC.expr.2 <- data.frame(BIC.sample.classes.filtered[,1], t(BIC.expr.DEGsorted))
names(BIC.expr.2)[1] <- "cancer.type"

# We use Random Forest as a classifier for our training dataset
BIC.expr.2$cancer.type = factor(BIC.expr.2$cancer.type) # randomForest expects categorical outcome variables to be factors so we convert the cancert.type column
rf.fit.allsamples <- randomForest(cancer.type ~ ., data = BIC.expr.2)

## 2. We use this model to predict the type of cancer for the unclassified samples
df.pred.unclas <- t(BIC.expr)[ind.uncl,]

pred.rf.unclas <- predict(rf.fit.allsamples, newdata = df.pred.unclas)

# We look at the predicted results for the unclassified samples
table(pred.rf.unclas)

```

```{r prediction_link_immuno}
# We look at the link between the predicted type of cancer gave to the unclassified samples and the immuno classes results
BIC.sample.classes.unclass <- BIC.sample.classes[BIC.sample.classes$cancer.type == "Unclassified",]

# Immuno classes ER1
table(pred.rf.unclas, BIC.sample.classes.unclass$ER1) 

# Immuno classes PR1    
table(pred.rf.unclas, BIC.sample.classes.unclass$PR1)

# Immuno classes Her2
table(pred.rf.unclas, BIC.sample.classes.unclass$Her2)
```


#### Your interpretation

Comment the general assignment of the unclassified samples to the different classes.  Analyse the relationship between the immuno markers and the predicted classes. 

Je retrouve le "biais" observ√© par apr√®s la classification supervis√© du testing set o√π il y a beaucoup plus d'√©chantillons qui sont classifi√©s comme √©tant Luminal.A et pas d'√©chantillons classifi√©s comme HER2pos. 

Je ne trouve pas que la relation entre les marqueurs immuno et les types de cancer soit vraiment √©vidente car si on prends au cas par cas:

  + Le marqueur ER1 devrait √™tre positif pour les cancers de type Luminal.A et .B uniquement et tous les √©chantillons Luminal.A ne sont pas positifs (m√™me si c'est seulement une petite fraction). De plus il y a des √©chantillons Basal.like positifs √† ce marqueur

  + Le marqueur PR1 devrait √™tre positif pour les cancers de type Luminal.A et .B uniquement et cela n'est pas le cas (avec des √©chantillons de basal.like aussi positifs et la plus grande majorit√© des √©chantillons luminal.A n√©gatifs √† ce marqueur)

  + Le marqueur Her2 devrait √™tre positif pour les cancers de type Luminal.B et HER2pos. Vu qu'aucun √©chantillon a √©t√© classifi√© comme cancer HER2pos, on ne peut rien dire concernant ce type de cancer. Par contre, on voit que m√™me si les 5 √©chantillons associ√©s √† Luminal.B sont positifs, il y a aussi 1/4 des √©chantillons LuminalA qui sont positifs alors qu'ils ne devraient pas l'√™tre.  

De mani√®re g√©n√©rale, la pr√©diction ne semble pas tr√®s "correcte". 

****************************************************************
## General conclusion and perspectives

(a few sentences, no more)

De mani√®re g√©n√©rale, les √©chantillons provenant des types de cancer Luminal A et B sont potentiellement assez diff√©rents des √©chantillons provenant des types de cancer Basal.like et HER2pos et il y aurait potentiellement des g√®nes diff√©rentiellement exprim√©s entre ces 2 "groupes" de cancer. La classification supervis√©e a surtout √©t√© "biais√©e" vers les √©chantillons de type LuminalA et donc le protocole utilis√© ne semble pas optimal pour bien classer les √©chantillons "unclassified". 

